Compare KraneShares Electric Vehicles and Future Mobility (KARS) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KraneShares Electric Vehicles and Future Mobility vs Zoetis Inc — how do they compare? KraneShares Electric Vehicles and Future Mobility trades at $29.85, while Zoetis Inc trades at $75.53 (market cap $31.95B). The key difference: Zoetis Inc pays a 2.78% dividend while KraneShares Electric Vehicles and Future Mobility pays none, and KraneShares Electric Vehicles and Future Mobility is trading nearer its 52-week high, Zoetis Inc nearer its low. Which is the better fit depends on your goals.
| KARS | ZTS | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $38.01 | $156.76 |
52-Week Low | $23.61 | $71.91 |
Market Cap | — | $31.95B |
Enterprise Value | — | $39.24B |
Dividend Yield | — | 2.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KARS trades at $29.15, down 0.98% with bearish technical signals across moving averages and oscillators. The stock shows oversold conditions with RSI at 27.23, while facing resistance at $30. Recent industry news highlights strong global EV sales growth and China's expanding market presence, though US adoption lags behind international markets.
The EV sector faces competitive pressures from Chinese manufacturers and regulatory uncertainty, while benefiting from rising fuel prices driving consumer demand. KARS's performance depends on broader industry trends rather than company-specific fundamentals, with technical indicators suggesting continued near-term pressure.
Zoetis (ZTS) trades at $75.33, down 1.61% amid mixed technical signals and ongoing securities litigation. The stock shows strong fundamentals with a 28.03% net margin and 67.75% ROE, supported by consistent revenue growth from $8.1B in 2022 to $9.47B in 2025. Recent earnings beat expectations in Q3 and Q4 2025 but missed in Q1 2026, with Q2 results pending. Analyst consensus remains positive with a $101.43 price target, though technical indicators show neutral momentum near key support at $75.
The outlook for ZTS is cautiously optimistic given robust profitability and analyst support, but significant legal overhangs and recent earnings volatility present near-term risks. Long-term growth in animal health markets offers upside, yet investors should monitor litigation developments and Q2 earnings for directional cues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About KraneShares Electric Vehicles and Future Mobility
KARS invests in the global electric vehicle ecosystem and future mobility. It tracks the Bloomberg Electric Vehicles Index, providing exposure to EV manufacturers, battery technology, and lithium miners like Tesla, BYD, and Albemarle.
Read more on KARS →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
